Griffen Securities Positive on ZIOPHARM's (ZIOP) Latest Membrane-Bound IL-15 Data; Affirms at 'Buy'
Tweet Send to a Friend
Griffen Securities reaffirms ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) at Buy with a price target of $21 after the company announced ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
